![](https://monteverdelaw.com/wp-content/uploads/case-logo/axonics-inc.jpg)
Axonics, Inc. (Nasdaq: AXNX), relating to its proposed sale to Boston Scientific Corp. Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.
Axonics, Inc. (Nasdaq: AXNX), relating to its proposed sale to Boston Scientific Corp. Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.